BR112017023751A2 - uso de um polipeptídeo para efetuar a sinalização imune e/ou afetar a função de barreira intestinal e/ou condição metabólica modular - Google Patents

uso de um polipeptídeo para efetuar a sinalização imune e/ou afetar a função de barreira intestinal e/ou condição metabólica modular

Info

Publication number
BR112017023751A2
BR112017023751A2 BR112017023751A BR112017023751A BR112017023751A2 BR 112017023751 A2 BR112017023751 A2 BR 112017023751A2 BR 112017023751 A BR112017023751 A BR 112017023751A BR 112017023751 A BR112017023751 A BR 112017023751A BR 112017023751 A2 BR112017023751 A2 BR 112017023751A2
Authority
BR
Brazil
Prior art keywords
polypeptide
metabolic condition
barrier function
intestinal barrier
immune signaling
Prior art date
Application number
BR112017023751A
Other languages
English (en)
Inventor
Belzer Clara
Meindert De Vos Willem
Daniel CANI Patrice
Original Assignee
Wageningen Universiteit
Université Catholique de Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wageningen Universiteit, Université Catholique de Louvain filed Critical Wageningen Universiteit
Publication of BR112017023751A2 publication Critical patent/BR112017023751A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

foi descoberto que um polipeptídeo extracelular derivado de akkermansia municiphila é capaz de modular e/ou promover a função do sistema imune da mucosa intestinal e/ou manter e/ou restaurar a condição metabólica e/ou aumentar a integridade física da barreira da mucosa intestinal em um mamífero. o polipeptídeo ou células hospedeiras compreendendo tal polipeptídeo podem ser utilizados para prevenir e/ou tratar uma variedade de condições que se beneficiam de uma integridade física aumentada da barreira da mucosa intestinal e/ou uma função melhorada do sistema imune da mucosa intestinal e da condição metabólica.
BR112017023751A 2015-05-06 2016-05-04 uso de um polipeptídeo para efetuar a sinalização imune e/ou afetar a função de barreira intestinal e/ou condição metabólica modular BR112017023751A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166598 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (1)

Publication Number Publication Date
BR112017023751A2 true BR112017023751A2 (pt) 2018-07-31

Family

ID=74184294

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023751A BR112017023751A2 (pt) 2015-05-06 2016-05-04 uso de um polipeptídeo para efetuar a sinalização imune e/ou afetar a função de barreira intestinal e/ou condição metabólica modular

Country Status (16)

Country Link
US (2) US10738089B2 (pt)
EP (1) EP3292135B1 (pt)
JP (1) JP6894382B2 (pt)
KR (1) KR20180011130A (pt)
CN (1) CN107980043B (pt)
AU (2) AU2016257315A1 (pt)
BR (1) BR112017023751A2 (pt)
CA (1) CA2984985A1 (pt)
DK (1) DK3292135T3 (pt)
EA (1) EA201700507A1 (pt)
ES (1) ES2934138T3 (pt)
HK (1) HK1252412A1 (pt)
IL (1) IL255405B (pt)
MX (1) MX2017014111A (pt)
PL (1) PL3292135T3 (pt)
WO (1) WO2016177797A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
DK3292135T3 (da) 2015-05-06 2022-10-31 Univ Wageningen Anvendelse af et polypeptid til at fremkalde immunsignalering og/eller påvirke tarmbarrierefunktion og/eller modulere metabolsk status
PT3626081T (pt) * 2015-09-10 2022-02-25 Univ Catholique Louvain Akkermansia pasteurizada para promover a perda de peso
EP3790889A4 (en) 2017-03-07 2022-06-08 Psomagen, Inc. DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS TARGETING TOLL-LIKE RECEPTORS AND METHODS THEREOF
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
EP3675882A4 (en) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
WO2020226438A1 (ko) * 2019-05-07 2020-11-12 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
CN115315433A (zh) * 2020-01-10 2022-11-08 黄志宏 Tlr2交互作用的胜肽以及包括其的组合物
WO2021194281A1 (ko) * 2020-03-25 2021-09-30 한국생명공학연구원 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
US20230265131A1 (en) 2020-07-01 2023-08-24 Wageningen Universiteit Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
KR20220061018A (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
JP3932358B2 (ja) * 2001-02-28 2007-06-20 独立行政法人産業技術総合研究所 ブラディオン遺伝子導入ショウジョウバエ株
AU2003296330A1 (en) * 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
US20050163764A1 (en) * 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5290177B2 (ja) 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
US20100172874A1 (en) 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
MY159273A (en) 2009-05-11 2016-12-30 Nestec Sa Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
JP5931076B2 (ja) 2010-10-20 2016-06-08 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 個別識別化装置
ES2565407T3 (es) 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
DK3292135T3 (da) 2015-05-06 2022-10-31 Univ Wageningen Anvendelse af et polypeptid til at fremkalde immunsignalering og/eller påvirke tarmbarrierefunktion og/eller modulere metabolsk status
PT3626081T (pt) 2015-09-10 2022-02-25 Univ Catholique Louvain Akkermansia pasteurizada para promover a perda de peso
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Also Published As

Publication number Publication date
IL255405A0 (en) 2017-12-31
CN107980043A (zh) 2018-05-01
US10738089B2 (en) 2020-08-11
US11466057B2 (en) 2022-10-11
AU2020267210B2 (en) 2023-10-12
JP6894382B2 (ja) 2021-06-30
HK1252412A1 (zh) 2019-05-24
EA201700507A1 (ru) 2018-05-31
EP3292135A1 (en) 2018-03-14
MX2017014111A (es) 2018-02-26
JP2018515502A (ja) 2018-06-14
DK3292135T3 (da) 2022-10-31
EP3292135B1 (en) 2022-09-21
CN107980043B (zh) 2021-09-24
ES2934138T3 (es) 2023-02-17
WO2016177797A1 (en) 2016-11-10
KR20180011130A (ko) 2018-01-31
US20180265554A1 (en) 2018-09-20
AU2016257315A1 (en) 2017-11-23
IL255405B (en) 2022-01-01
US20210147489A1 (en) 2021-05-20
PL3292135T3 (pl) 2023-01-02
AU2020267210A1 (en) 2020-12-17
CA2984985A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
BR112017023751A2 (pt) uso de um polipeptídeo para efetuar a sinalização imune e/ou afetar a função de barreira intestinal e/ou condição metabólica modular
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
BR112017004826A2 (pt) terapias de combinação de inibidores de alk
BR112017007543A2 (pt) peptídeos com propriedades anti-inflamatórias
BR112017012817A2 (pt) agente de clivagem de película líquida
BR112016025297A2 (pt) adenovírus que compreende uma porção de ligação a albumina
MX2017004708A (es) Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
BR112016026264A2 (pt) sistema e método dos mesmos para otimizar o tempo de inicialização de computadores com múltiplas cpus.
EP4275705A3 (en) Pancreatitis treatment
BR112016015851A2 (pt) Formulações farmacêuticas estabilizadas de insulina aspart
DK3075256T3 (da) Bearbejdnings- og/eller inspektionslinie for fjerkræ ophængt i benene
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
DK3145480T3 (da) Særlig fremstillede kosmetiske og/eller dermatologiske produkter
DK3429559T3 (da) Velsmagende sammensætninger indeholdende natriumphenylbutyrat og anvendelser deraf
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
KR20180084632A (ko) 섭취에 적합한 디바이스 및 연관된 시스템
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
MX2015014307A (es) Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
BR112017009189A2 (pt) célula hospedeira recombinante expressando atividade de beta-galactosidase e/ou transgalactosilante deficiente em mananase, celulase e pectinase
DK3233110T3 (da) Cyklisk acetylcholinesterase-c-terminalt peptid i behandling eller forebyggelse af cancer eller metastase
GB2559471B (en) Computer system having redundant power supply and system board
BR112017028052A2 (pt) peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]